These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 25987371

  • 1. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
    Ohashi M, Oyama T, Miyachi H.
    Bioorg Med Chem Lett; 2015 Jul 01; 25(13):2639-44. PubMed ID: 25987371
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
    Ohashi M, Gamo K, Oyama T, Miyachi H.
    Bioorg Med Chem Lett; 2015 Jul 15; 25(14):2758-62. PubMed ID: 26025876
    [Abstract] [Full Text] [Related]

  • 3. Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist.
    Miyachi H.
    Int J Mol Sci; 2023 Feb 15; 24(4):. PubMed ID: 36835351
    [Abstract] [Full Text] [Related]

  • 4. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
    Hamuro Y, Coales SJ, Morrow JA, Molnar KS, Tuske SJ, Southern MR, Griffin PR.
    Protein Sci; 2006 Aug 15; 15(8):1883-92. PubMed ID: 16823031
    [Abstract] [Full Text] [Related]

  • 5. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R, Saccoccia F, Scotti E, Crestani M, Godio C, Gilardi F, Loiodice F, Fracchiolla G, Laghezza A, Tortorella P, Lavecchia A, Novellino E, Mazza F, Aschi M, Pochetti G.
    J Med Chem; 2008 Dec 25; 51(24):7768-76. PubMed ID: 19053776
    [Abstract] [Full Text] [Related]

  • 6. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T, Shiraki T, Oyama T, Fujimoto Y, Maebara K, Kamiya N, Jingami H, Morikawa K.
    J Mol Biol; 2009 Jan 09; 385(1):188-99. PubMed ID: 18977231
    [Abstract] [Full Text] [Related]

  • 7. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
    Jang JY, Koh M, Bae H, An DR, Im HN, Kim HS, Yoon JY, Yoon HJ, Han BW, Park SB, Suh SW.
    Biochim Biophys Acta Proteins Proteom; 2017 Jun 09; 1865(6):674-681. PubMed ID: 28342850
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.
    Ohashi M, Oyama T, Putranto EW, Waku T, Nobusada H, Kataoka K, Matsuno K, Yashiro M, Morikawa K, Huh NH, Miyachi H.
    Bioorg Med Chem; 2013 Apr 15; 21(8):2319-2332. PubMed ID: 23490155
    [Abstract] [Full Text] [Related]

  • 9. Molecular dynamics study-guided identification of cyclic amine structures as novel hydrophobic tail components of hPPARγ agonists.
    Tanaka Y, Gamo K, Oyama T, Ohashi M, Waki M, Matsuno K, Matsuura N, Tokiwa H, Miyachi H.
    Bioorg Med Chem Lett; 2014 Aug 15; 24(16):4001-5. PubMed ID: 25017035
    [Abstract] [Full Text] [Related]

  • 10. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S, Matter H, Schönafinger K, Glien M, Mathieu M, Marquette JP, Michot N, Haag-Diergarten S, Urmann M, Wendler W.
    ChemMedChem; 2011 Apr 04; 6(4):633-53. PubMed ID: 21400663
    [Abstract] [Full Text] [Related]

  • 11. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.
    Rikimaru K, Wakabayashi T, Abe H, Tawaraishi T, Imoto H, Yonemori J, Hirose H, Murase K, Matsuo T, Matsumoto M, Nomura C, Tsuge H, Arimura N, Kawakami K, Sakamoto J, Funami M, Mol CD, Snell GP, Bragstad KA, Sang BC, Dougan DR, Tanaka T, Katayama N, Horiguchi Y, Momose Y.
    Bioorg Med Chem; 2012 May 15; 20(10):3332-58. PubMed ID: 22503460
    [Abstract] [Full Text] [Related]

  • 12. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
    Gani OA, Sylte I.
    Chem Biol Drug Des; 2008 Jul 15; 72(1):50-7. PubMed ID: 18554251
    [Abstract] [Full Text] [Related]

  • 13. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
    dos Santos JC, Bernardes A, Giampietro L, Ammazzalorso A, De Filippis B, Amoroso R, Polikarpov I.
    J Struct Biol; 2015 Sep 15; 191(3):332-40. PubMed ID: 26185032
    [Abstract] [Full Text] [Related]

  • 14. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
    Puhl AC, Bernardes A, Silveira RL, Yuan J, Campos JL, Saidemberg DM, Palma MS, Cvoro A, Ayers SD, Webb P, Reinach PS, Skaf MS, Polikarpov I.
    Mol Pharmacol; 2012 Jun 15; 81(6):788-99. PubMed ID: 22391103
    [Abstract] [Full Text] [Related]

  • 15. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
    Peng YH, Coumar MS, Leou JS, Wu JS, Shiao HY, Lin CH, Lin WH, Lien TW, Chen X, Hsu JT, Chao YS, Huang CF, Lyu PC, Hsieh HP, Wu SY.
    ChemMedChem; 2010 Oct 04; 5(10):1707-16. PubMed ID: 20734309
    [Abstract] [Full Text] [Related]

  • 16. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.
    Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV.
    Nature; 1998 Sep 10; 395(6698):137-43. PubMed ID: 9744270
    [Abstract] [Full Text] [Related]

  • 17. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
    Kuwabara N, Oyama T, Tomioka D, Ohashi M, Yanagisawa J, Shimizu T, Miyachi H.
    J Med Chem; 2012 Jan 26; 55(2):893-902. PubMed ID: 22185225
    [Abstract] [Full Text] [Related]

  • 18. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Sheu SH, Kaya T, Waxman DJ, Vajda S.
    Biochemistry; 2005 Feb 01; 44(4):1193-209. PubMed ID: 15667213
    [Abstract] [Full Text] [Related]

  • 19. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
    Mahindroo N, Wang CC, Liao CC, Huang CF, Lu IL, Lien TW, Peng YH, Huang WJ, Lin YT, Hsu MC, Lin CH, Tsai CH, Hsu JT, Chen X, Lyu PC, Chao YS, Wu SY, Hsieh HP.
    J Med Chem; 2006 Feb 09; 49(3):1212-6. PubMed ID: 16451087
    [Abstract] [Full Text] [Related]

  • 20. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.
    Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, Allison P, Yuan H, Baker DL, Li Z, Bittman R, Parrill A, Tigyi G.
    J Biol Chem; 2006 Feb 10; 281(6):3398-407. PubMed ID: 16321982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.